Open company graph database — free web & API
Login

Daito Corporation

ダイト株式会社Daito Pharmaceutical Co., Ltd.Alias(Daito Pharmaceutical Co., Ltd.)Alias
Ticker
Listed market
TYO
Country
Japan
Employees (consolidated)
987
Related companies
25
§01

Basic information

BASIC
Head office
326 Yokancho, Toyama City, Toyama Prefecture, 939-8567Sources
Chief executive
Koji MatsumoriSources
Capital
7,186,190,000  (71 100 million)
Employees (non-consolidated)
987 people
Employees (consolidated)
987 people
Start date
1942-06-01
End date
§02

Websites

1 DOMAINS
§03

Business

3
Pharmaceutical manufacturing and salesSourcesPharmaceutical wholesale salesSourcesAnimal pharmaceutical wholesale salesSources
§04

Related companies

25 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Daito Pharmaceuticals America, Inc. SourcesSources
Group Subsidiary
Da Tong Pharmaceutical (China) Co., Ltd. SourcesSources
Group Subsidiary
Anhui Dingwang Pharmaceutical Co., Ltd. SourcesSources
Group Shareholder
Felsen Pharma Co., Ltd. SourcesSources
Group
Qianhui Pharmaceutical (Anhui) Co., Ltd. SourcesSources
Group Shareholder
Astellas Pharma Inc. Sources
Customer
Arinamin Pharmaceutical Co., Ltd. Sources
Customer
Eisai Co., Ltd. Sources
Customer
Tohoku Sand Co., Ltd. Sources
Customer
Shionogi Healthcare Co., Ltd. Sources
Customer
Nobel Pharma Co., Ltd. Sources
Customer
Viatris Pharmaceuticals Inc. Sources
Customer
Sumitomo Pharma Co., Ltd. Sources
Customer
ONO PHARMACEUTICAL CO., LTD. Sources
Customer
Teijin Pharma Co., Ltd. Sources
Customer
Fuso Pharmaceutical Industries, Ltd. Sources
Customer
Nichi Iko Co., Ltd. Sources
Customer
Towa Pharmaceutical Co., Ltd. Sources
Customer
Takeda Pharmaceutical Company, Limited Sources
Customer
Sawai Pharmaceutical Co., Ltd. Sources
Customer
Tanabe Pharma Factory Co., Ltd. Sources
Customer
Kaken Pharmaceutical Co., Ltd. Sources
Customer
Daiichi Sankyo Healthcare Co., Ltd. Sources
Customer
Nomura Investor Relations Co., Ltd.
千輝薬業(安徽)有限責任会社 (中国)
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

86 EVENTS

Established in 1942 as a company controlling the export of Toyama household medicines. Founded Dai-Do Pharmaceutical Trading Control Co., Ltd.Sources

Established as a company controlling the export of Toyama household medicine to Southeast Asia, where many Japanese residents lived. Founded Daito Pharmaceutical Trade Control Co., Ltd.Sources

Founded in 1942 as an export control company for Toyama Household Medicine, the company celebrated its 10th anniversary of stock listing in 2020.Sources

Established Dai Toa Pharmaceutical Trading Control Co., Ltd. in 1942 (Showa 17)Sources

Founded: June 1942 (Showa 17).Sources

In 1948, changed the company name to Dai-Do Trading Co., Ltd.Sources

Changed the company name to Daito Trade Co., Ltd.Sources

Changed company name to Dai To Trading Co., Ltd. in 1948 (Showa 23)Sources

In 1949, began manufacturing prescription drugs.Sources

Commenced manufacturing of allocation medicines.Sources

Started manufacturing distribution-use pharmaceuticals in 1949 (Showa 24)Sources

In 1950, established the raw material wholesale division and began selling raw materials.Sources

Established the Active Pharmaceutical Ingredient Wholesale Division and began selling APIs in 1950 (Showa 25)Sources

From 1961, the national health insurance system began, and medical care became widely available.Sources

In 1971, established a research laboratory in Toyama City.Sources

Established a research institute in Toyama City.Sources

Established a research institute in Toyama City in 1971 (Showa 46)Sources

In 1976, began manufacturing generic medical drugs.Sources

Commenced manufacturing of medical drugs (generic drugs).Sources

Started manufacturing generic medical drugs in 1976 (Showa 51)Sources

In 1979, began manufacturing raw materials.Sources

Commenced manufacturing of active pharmaceutical ingredients.Sources

Started manufacturing APIs in 1979 (Showa 54)Sources

In 1985, began manufacturing OTC drugs.Sources

Started manufacturing OTC pharmaceuticalsSources

Started manufacturing OTC drugs in 1985 (Showa 60)Sources

In 1987, acquired Daiwa Pharmaceutical Industry Co., Ltd. (now Daito Co., Ltd. Shimokoi Factory) as a subsidiary.Sources

Acquired Daiwa Pharmaceutical Industries Co., Ltd. (now Daito Corporation, Shimauchi Factory) as a subsidiarySources

Made Daiwa Pharmaceutical Industries Co., Ltd. (now Daito Co., Ltd. Shimokoi Factory) a subsidiary in 1987 (Showa 62)Sources

In 1989, began contract manufacturing of new drug intermediates.Sources

Commenced contract manufacturing of new drug intermediatesSources

Started contract manufacturing of new drug intermediates in 1989 (Showa 64)Sources

In 1991, changed the company name to Daito Co., Ltd.Sources

Changed the company name to Daito CorporationSources

Changed company name to Daito Co., Ltd. (current name) in 1991 (Heisei 3)Sources

In 1993, established the third manufacturing building.Sources

Established a new third formulation buildingSources

Established the Third Formulation Building in 1993 (Heisei 5)Sources

In 1999, established the third raw material building.Sources

Established a new third active pharmaceutical ingredient buildingSources

Established the Third Active Pharmaceutical Ingredient Building in 1999 (Heisei 11)Sources

With the 2005 revision of the Pharmaceutical Affairs Law, the contract manufacturing business for medical drugs expanded.Sources

In 2007, listed shares on the Tokyo Stock Exchange.Sources

Established a new fifth active pharmaceutical ingredient buildingSources

Fully acquired Daiwa Pharmaceutical Industries Co., Ltd. (now Daito Corporation, Shimauchi Factory) as a subsidiarySources

In 2007 (Heisei 19), the Fifth Active Pharmaceutical Building was newly established, and Daito Pharmaceutical Industry Co., Ltd. (now Daito Co., Ltd. Shimokui Plant) was fully acquired as a subsidiary.Sources

In 2008, established Daito Pharmaceuticals America, Inc. in Illinois, USA.Sources

Established Daito Pharmaceuticals America, Inc. in Illinois, USASources

Established a new sixth formulation buildingSources

In 2008 (Heisei 20), Daito Pharmaceuticals America, Inc. was established in Illinois, USA, and the Sixth Formulation Building was newly established.Sources

Listed on the Second Section of the Tokyo Stock Exchange in 2010.Sources

Listed on the Second Section of the Tokyo Stock ExchangeSources

In 2010 (Heisei 22), the company was listed on the Second Section of the Tokyo Stock Exchange.Sources

Reclassified to the First Section of the Tokyo Stock Exchange in 2011.Sources

Reclassified to the First Section of the Tokyo Stock ExchangeSources

In 2011 (Heisei 23), the company was moved to the First Section of the Tokyo Stock Exchange, and Daito Pharmaceuticals America, Inc.Sources

Acquired Anhui Weina Life Science Technology Development Co., Ltd. (now Da Tong Pharmaceutical (China) Co., Ltd.) as a subsidiary in 2012.Sources

Acquired Anhui Weina Life Science Technology Development Co., Ltd. as a subsidiarySources

In 2012 (Heisei 24), Anhui Weina Life Science and Technology Development Co., Ltd. was acquired as a subsidiary (now Daitoki Pharmaceutical (China) Co., Ltd.).Sources

Established a new formulation building at Da Tong Pharmaceutical (China) Co., Ltd. in 2014. Opened the Seventh Formulation Building for high pharmacological active formulation manufacturing.Sources

Established a formulation building at Daikou Pharmaceutical (China) Co., Ltd.Sources

Established a new seventh formulation building (high pharmacological activity formulation production)Sources

Established the first factory building of Daiwa Pharmaceutical Industries (now Daito Corporation, Shimauchi Factory)Sources

In 2014 (Heisei 26), a formulation building was newly established at Daitoki Pharmaceutical (China) Co., Ltd., the Seventh Formulation Building was newly established (for high pharmacological activity formulations), and the First Factory Building of Daito Pharmaceutical (now Daito Co., Ltd. Shimokui Plant) was newly established.Sources

Transitioned from a company with a board of auditors to one with an audit and other committees in 2015.Sources

Transitioned from a company with a board of auditors to a company with an audit committeeSources

Established a new sixth active pharmaceutical ingredient buildingSources

In 2015 (Heisei 27), the company transitioned from a company with a board of auditors to a company with an audit committee, and the Sixth Active Pharmaceutical Building was newly established.Sources

Established a high pharmacology R&D Center in 2017.Sources

Established a high pharmacology R&D centerSources

In 2017 (Heisei 29).Sources

Opened the Eighth Formulation Building for high pharmacological active formulation manufacturing in 2018.Sources

Established a new eighth formulation building (high pharmacological activity formulation production)Sources

Celebrated the 10th anniversary of the stock listing.Sources

In 2020, the company celebrated its 10th anniversary since going public.Sources

Established a Quality Assurance Building in 2021.Sources

New Quality Assurance Building establishedSources

Moved to the Prime Market following the Tokyo Stock Exchange market classification review in 2022.Sources

Transitioned to the Prime Market following a review of market classifications by the Tokyo Stock ExchangeSources

New Seventh Active Pharmaceutical Ingredient Building establishedSources

Opened the Tenth Formulation Building in 2023.Sources

New Tenth Formulation Building establishedSources

Established a Comprehensive Research Center in 2024.Sources

New Comprehensive Research Center establishedSources

Absorbed and merged with Daiwa Pharmaceutical Industries Co., Ltd. (now Daito Co., Ltd. Shimokoi Factory) in 2025.Sources

Absorbed and merged with Daiwa Pharmaceutical Industries Co., Ltd. (now Daito Co., Ltd. Shimokoi Factory)Sources

§07

News

2 ARTICLES

Daito Corporation Launches Four New Medical DrugsSources

Daito Corporation launched four new medical drugs, including Capecitabine Tablets 300mg "Takata" and Lacosamide products, on December 5, 2025. This is expected to expand options in medical settings.

Notice of the Passing of Kiyotaka Kido, President of Daiwa Pharmaceutical Industry Co., Ltd.Sources

Kiyotaka Kido, President of Daiwa Pharmaceutical Industry Co., Ltd., passed away peacefully on May 9, 2025. He was 70 years old. Daiwa Corporation sincerely thanks him for his lifelong friendship and mourns his passing.

§09

Sources & updates

SOURCES
↑